• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Rare Diseases

    PTC Withdraws US Approval Filing For Duchenne Drug Translarna

    FIERCE PHARMA

    PTC Therapeutics Provides Regulatory Update On Translarna

    PR NEWSWIRE

    PTC Therapeutics Gets Japan Approval For Sephience In (PKU)

    PR NEWSWIRE BIO

    RareMed Announces Expansion of Relationship with PTC Therapeutics

    PR NEWSWIRE

    PTC Therapeutics Receives CRL for Vatiquinone NDA

    PRESS RELEASE

    Orsini Chosen as PTC Therapeutics` Sephience Pharmacy Partner

    PR NEWSWIRE

    US FDA approves PTC Therapeutics` Metabolic Disorder Drug

    REUTERS

    Sephience Gets EU OK for PKU Drug Sepiapterin

    PR NEWSWIRE

    Sephience (Sepiapterin) Approved by European Commission for PKU

    PR NEWSWIRE

    PTC Therapeutics Gets Positive CHMP Opinion for Sephience for PKU

    PR NEWSWIRE

    FDA Priority Review To PTC’s Vatiquinone For Friedreich’s Ataxia

    PR NEWSWIRE

    FDA approves PTC Therapeutics` gene therapy for ultra-rare disorder

    REUTERS

    Technical Analysis of PTC Therapeutics

    TRADINGVIEW

    PTC plots path to rare disease approval despite phase 3 fail

    FIERCE BIOTECH

    PTC Therapeutics: A Gem In The Rare Diseases Treatment Market

    SEEKING ALPHA

    Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as CEO of PTC Therapeutics

    PR NEWSWIRE

    NICE backs PTC Therapeutics` gene therapy for ultra-rare disease

    FIERCE PHARMA

    NICE signs off on rare disease therapies from Alnylam, PTC

    FIERCE PHARMA

    COVID-19 Delaying Rare Disease and Gene Therapy Trials, Pharma Execs Say

    HEMOPHILIANEWSTODAY

    PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program

    PR NEWSWIRE

    Idorsia sheds surplus DMD therapy to Santhera

    FIERCE BIOTECH

    PTC Therapeutics to Acquire Agilis Biotherapeutics

    PR NEWSWIRE

    PTC Therapeutics Announces R&D Day to Review Multiple Orphan Disorder Programs

    PRESS RELEASE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.